Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 8/20 | 0.51 |
| ▸ | CA9 | Q16790 | 8/20 | 0.51 |
| ▸ | CA12 | O43570 | 6/20 | 0.51 |
| ▸ | CA1 | P00915 | 6/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4414333 | 0.81 | CA2 (0.50) | S1PR1CA2CA9CA12CA1 | |
| SCHEMBL5569323 | 0.81 | DPP4 (0.53) | S1PR1CA2CA9CA12CA1 | |
| SCHEMBL4956338 | 0.81 | HDAC4 (0.53) | S1PR1CA2CA9CA12CA1 | |
| SCHEMBL26096203 | 0.79 | NPC1 (0.64) | S1PR1CA2CA9CA12CA1 | |
| SCHEMBL19047572 | 0.78 | HDAC4 (0.72) | HDAC4HDAC6 | |
| SCHEMBL17100937 | 0.76 | NR1H4 (0.68) | MEN1LMNAKMT2ANR1H4 | |
| SCHEMBL19555861 | 0.75 | NOTUM (0.61) | KMT2ANR1H4 | |
| SCHEMBL22807038 | 0.75 | PTGS2 (0.60) | S1PR1PTGS2MEN1LMNAKMT2A | |
| SCHEMBL22757158 | 0.73 | CA2 (0.76) | S1PR1CA2CA9CA12CA1 | |
| SCHEMBL14282771 | 0.72 | NR1H4 (0.60) | CA2CA9CA12CA1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| CN-101287729-A | GPCR agonists | PROSIDION LTD (GB) | 2008-10-15 | — | — | CN | disclosed |
| EP-1907383-A1 | GPCR AGONISTS | Prosidion Limited (GB) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007003960-A1 | GPCR AGONISTS | PROSIDION LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007003960-A1 | GPCR AGONISTS | PROSIDION LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325924-A1 | GPCR Agonists | GPR119, GCGR, GPR27 | S1PR1 308/4885CA2 3541/4885CA9 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.